FDA · 新闻稿·· 29 天前AI 评分22
两周内四项FDA决定:GSK乙肝药物领跑,Inovio股价今年已跌超40%
Four FDA Decisions in Two Weeks: GSK's Hepatitis B Drug Leads the Pack as Inovio Shares Have Already Fallen Over 40% This Year - BigGo Finance
AI 导读
未来两周FDA将作出四项审评决定,GSK的乙肝药物处于领先位置。Inovio股价今年以来已下跌超过40%。
来源:FDA · 新闻稿 · news.google.com